The Food and Drug Administration, which has had a tough month by any standard, is on the defensive in response to numerous stakeholders questioning its ability to perform as a watchdog in its current form.
FDA commissioner Andrew von Eschenbach was hauled before the House Committee on Oversight and Government Reform to discuss Avandia, GlaxoSmithKline's diabetes drug that some studies say may increase the risk of heart failure. Despite the FDA announcing it would put its strictest warning on the drug, ...